Evidence map›Paper›PMID 34913533›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2022

Tumor-Associated Immune-Cell-Mediated Tumor-Targeting Mechanism with NIR-II Fluorescence Imaging.

Homan Kang, Md Shamim, Xiaoran Yin, Eeswar Adluru, Takeshi Fukuda, Shinya Yokomizo, Hyejin Chang, Seung Hun Park, Yanan Cui, Austin J Moy and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. HMolecules (Basel, Switzerland) · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Homan KangGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.ORCID https://orcid.org/0000-0002-0732-9779
Md ShamimDepartment of Chemistry, Center of Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, 30303, USA.
Xiaoran YinGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Eeswar AdluruGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Takeshi FukudaGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Shinya YokomizoGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Hyejin ChangDivision of Science Education, Kangwon National University, Chuncheon, 24341, South Korea.
Seung Hun ParkGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Yanan CuiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Austin J MoyTrifoil Imaging, 9449 De Soto Ave, Chatsworth, CA, 91311, USA.
Satoshi KashiwagiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Maged HenaryDepartment of Chemistry, Center of Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, 30303, USA.
Hak Soo ChoiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.ORCID https://orcid.org/0000-0002-7982-6483

Funding

Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.R01EB022230 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI CHOI, HAK SOO, HENARY, MAGED M · 2017 to 2020
$3.6M
Nanochelation Therapies for Iron Overload DisordersR01HL143020 · NHLBI · UNIVERSITY OF MASSACHUSETTS LOWELL · PI CHOI, HAK SOO, KIM, JONGHAN · 2018 to 2021
$2.6M
Creative Materials Discovery ProgramNational Research Foundation of Korea 2019M3D1A1078938NHLBI NIH HHS #R01HL143020NHLBI NIH HHS R01 HL143020NHLBI NIH HHS R01HL143020NIBIB NIH HHS #R01EB022230NIBIB NIH HHS R01 EB022230NIBIB NIH HHS R01EB022230
6 · The paper itself

Abstract

The strategy of structure-inherent tumor targeting (SITT) with cyanine-based fluorophores is receiving more attention because no chemical conjugation of targeting moieties is required. However, the targeting mechanism behind SITT has not yet been well explained. Here, it is demonstrated that heptamethine-cyanine-based fluorophores possess not only targetability of tumor microenvironments without the need for additional targeting ligands but also second near-infrared spectral window (NIR-II) imaging capabilities, i.e., minimum scattering and ultralow autofluorescence. The new SITT mechanism suggests that bone-marrow-derived and/or tissue-resident/tumor-associated immune cells can be a principal target for cancer detection due to their abundance in tumoral tissues. Among the tested, SH1 provides ubiquitous tumor targetability and a high tumor-to-background ratio (TBR) ranging from 9.5 to 47 in pancreatic, breast, and lung cancer mouse models upon a single bolus intravenous injection. Furthermore, SH1 can be used to detect small cancerous tissues smaller than 2 mm in diameter in orthotopic lung cancer models. Thus, SH1 could be a promising cancer-targeting agent and have a bright future for intraoperative optical imaging and image-guided cancer surgery.

Indexed as

NeoplasmsSurgery, Computer-AssistedAnimalsFluorescent DyesMiceOptical ImagingTumor MicroenvironmentFluorescent Dyesoptical imagingsecond near-infrared spectral window (NIR-II)tumor-associated immune cellstumor microenvironmenttumor targeting

Identifiers

PMID34913533
PMCPMC8881361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.